Zota Health Care Limited share price
NSE: ZOTA · ISIN INE358U01012
Key numbers
- Market cap
- ₹ 4,629 Cr
- Current price
- ₹ 1,336.60
- 52-week high / low
- ₹ 1,740 / 1,022
- Stock P/E
- -
- Book value
- ₹ 200.2
- Dividend yield
- 0.07%
- ROCE
- -9.9%
- ROE
- -16.1%
- Debt to equity
- 0.39
- Sales growth (3 yrs)
- 56.7%
- Profit growth (3 yrs)
- -
- 1-year return
- -8.8%
About Zota Health Care Limited
Zota Health Care Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company offers pharmaceutical, nutraceutical, ayurvedic, and over-the-counter products. It also provides various medicines for chronic ailments, such as diabetes, cardiac, and thyroid disorders. The company operates its retail stores under the DAVAINDIA name. Zota Health Care Limited was founded in 1995 and is headquartered in Surat, India.
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 97 | 104 | 143 | 163 | 174 |
| Operating profit | 2 | 4 | -0 | 9 | -12 |
| Net profit | -13 | -14 | -30 | -14 | -44 |
| EPS (₹) | -4.57 | -4.92 | -9.44 | -4.13 | -12.58 |
Concall summary (2026-08-20)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- These have risen as a percentage of revenue and currently stand at around 33%, compared to about 21% in Q1 FY26.
- Further, the 617 stores opened during FY25 have already reached around INR2.28 lakh in monthly revenue per store as of the last quarter, which indicates that they are nearing maturity.
Growth & demand
- During the quarter, revenue from operations grew to 67.6% Y-O-Y basis to INR 17,360 lakhs, driven primarily by expansion of the Davaindia network and growth in existing stores.
- For example, last year these stores delivered approximately 7.5% quarter -on-quarter growth, translating into annualized growth of roughly 30%.
Margins & costs
- At this revenue level, store-level EBITDA margins are typically in the range of 12% to 15%, indicating that these stores are already operating at a profitable level.
- In the fourth year, margins reach approximately 20-22%, and by the fifth year, stores usually achieve around 30% store-level EBITDA margins.
Capex & expansion
- During the 1st Quarter we delivered robust growth across our operations, supported by a sustained expansion of the Davaindia Network and increasing consumer acceptance of affordable healthcare solutions.
- One of the key highlights of the quarter was the continued expansion of the retail footprint.
Balance sheet & cash
- Once we have engaged a brand ambassador of Dhoni's stature, it is important to actively leverage that association through brand- building and promotional activities.
- Zota Health Care Limited August 14, 2026 We expect this quarterly cash loss of around INR20 crore to be eliminated over the next two to three quarters as store productivity improves and operating leverage kicks in.
Peers in Biotechnology
Data for information only, not investment advice. Prices end of day.